ReviewJournal of dental sciences2026
Epigallocatechin gallate in dentistry: Therapeutic applications, biomaterial integration, and translational challenges.
Review in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigallocatechin gallate (EGCG), a major bioactive catechin in green tea, has attracted increasing attention in dentistry because of its antioxidant, anti-inflammatory, antimicrobial, matrix-modulating, and regenerative properties. This narrative review summarizes current evidence on the biological mechanisms, dental applications, and translational challenges of EGCG in oral healthcare. EGCG can modulate oxidative stress and inflammatory signaling pathways, including nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), nuclear factor erythroid 2-related factor 2/heme oxygenase-1 (Nrf2/HO-1), and NOD-like receptor family pyrin domain containing 3 (NLRP3)-related responses, and has activity against oral disease-associated microorganisms and biofilms. In periodontal therapy, EGCG has been investigated as an adjunct to non-surgical periodontal treatment and as a local therapeutic agent through gingival patches, injectable hydrogels, and other delivery systems. In adhesive and restorative dentistry, EGCG may improve resin-dentin interface stability through matrix metalloproteinase inhibition, dentin biomodification, and antimicrobial effects against cariogenic biofilms. In regenerative dentistry, EGCG has been reported to promote osteogenic and odontogenic differentiation, regulate immune responses, support angiogenesis, and enhance bone-related repair when incorporated into scaffolds, membranes, hydrogels, or bioactive coatings. However, most evidence remains derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.